- Provides strategies for the development of safe and efficacious novel formulations for various modalities of biologics, vaccines and for cancer therapy
- Highlights novel cases from current clinical trials as well as marketed products
- Reviews overall successes and challenges in the development of novel formulations, including new molecular targets for the treatment of diseases, design of target-specific therapies, regulatory considerations, individualized therapies
Section I: NOVEL THERAPEUTIC APPROACHES 1. Clinical Considerations in the Design, Evaluation and Development of Novel Therapies 2. New Era in Gene Therapy 3. Advances in Nanotechnology-Based Drug Delivery Platforms and Novel Drug Delivery Systems 4. Novel Approaches for the Delivery of Biologics to the Central Nervous System 5. Trends in Nonparenteral Delivery of Biologics, Vaccines and Cancer Therapies
Section II: NOVEL APPROACHES FOR BIOLOGICS 6. Novel Generation of Antibody-Based Therapeutics 7. Novel Approaches in Discovery and Design of Antibody-Based Therapeutics 8. Novel Therapeutic Proteins and Peptides 9. Biobetter Biologics
Section III: NOVEL APPROACHES FOR VACCINES 10. Vaccines Against Non-Infectious, Non-Cancer Novel Targets 11. Winning a Race Against Evolving Pathogens with Novel Platforms and Universal Vaccines 12. Prime-Boost Vaccination: Impact on the HIV Vaccine Field
Section IV: NOVEL APPROACHES FOR CANCER THERAPIES
IV.I Novel Therapeutic Approaches and Targets for Cancer 13. Personalized Therapies for Cancer Treatment 14. Hunting Molecular Targets for Anticancer Reagents by Chemical Proteomics
IV.II Novel Immunotherapies for Cancer 15. Cancer Vaccines 16. T-Cell Immunotherapy for Cancer 17. Immunostimulators and Immunomodulators in Cancer Treatment
IV.III Novel Approaches for Cancer Therapy with Small Molecules 18. Long-Circulating Therapies for Cancer Treatment 19. Recent Advances and Trends in the Brain Delivery of Small Molecule Based Cancer Therapies
Manmohan Singh, Ph.D. is a well-known expert in the area of vaccine formulations and adjuvant research and has been working in vaccine R&D for the last 20 years. He has authored over 120 peer reviewed manuscripts, review articles and book chapters in this area. Dr. Singh is on the editorial board of 9 International Journals . He is also the editor of several books on vaccine delivery systems and adjuvants. He is currently working as the Head of Global Drug Product Development at Novartis Vaccines in Holly Springs, NC, U.S.A.
Maya Salnikova, Ph.D. is a well-known expert in the area of biologics, biosimilars and vaccine formulations. She has been working on development of novel formulations for the past 10 years in academia and industry. She has authored over 20 peer reviewed articles and book chapters. Dr. Salnikova is on the board of reviewers for Journal of Pharmaceutical Sciences and has contributed in organizing of international conferences. She is currently working as Drug Product Development Lead at Novartis Vaccines in Holly Springs, NC, U.S.A.